WHAT IS CLAIMED IS:

1. An isolated IL-23p19 antibody, wherein said antibody is fully human generated from phage display and binds to human IL-23p19 or a fragment thereof.

2. The isolated antibody of claim 1, wherein said antibody binds to human IL-23p19 at one or more of amino acid residues 93-105 of SEQ ID NO:145.

3. An isolated IL-23p19 antibody, comprising at least one light chain variable region, said light chain variable region comprising at least one member from the group consisting of:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOS:46-51;

a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOS:52-57; and

a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NOS:58-79.

4. An isolated IL-23p19 antibody, comprising at least one heavy chain variable region, said heavy chain variable region comprising at least one member from the group consisting of:

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence selected from the group consisting of SEQ ID NOS:1-6;

a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOS:7-39 and 146; and

a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NOS:40-45.

5. An isolated IL-23p19 antibody, comprising the light chain variable region of claim 3 and the heavy chain variable region of claim 4.

6. The isolated IL-23p19 antibody of claim 5, further comprising at least one human framework region adjacent to the at least one complementarity determining region.

7. An isolated IL-23p19 antibody, comprising at least one light chain variable region, said light chain variable region comprising:

a complementarity determining region light chain 1 (CDRL1) amino acid sequence selected from the group consisting of SEQ ID NOS:46-51;

a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NOS:52-57; and

a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NOS:58-79.

8. An isolated IL-23p19 antibody, comprising at least one heavy chain variable region, said heavy chain variable region comprising:

a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence selected from the group consisting of SEQ ID NOS:1-6;

a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NOS:7-39 and 146; and

a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NOS:40-45.

9. An isolated IL-23p19 antibody, comprising the light chain variable region of claim 7 and the heavy chain variable region of claim 8.

10. An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence selected from the group consisting of SEQ ID NOS:82-85, 93-98, 100, 102, 113-116, and 128-132.

11. An isolated IL-23p19 antibody, comprising a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NOS:80, 81, 86-92, 99, 101, 103-112, 117-127, and 147.

12. An isolated IL-23p19 antibody, comprising the light chain variable region of claim 10 and the heavy chain variable region of claim 11.

13. An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence having at least 95% identity to any of the amino acid sequences selected from the group consisting of SEQ ID NOS: 82-85, 93-98, 100, 102, 113-116, and 128-132.

14. An isolated IL-23p19 antibody, comprising a heavy chain variable region amino acid sequence having at least 95% identity to any of the amino acid sequences selected from the group consisting of SEQ ID NOS: 80, 81, 86-92, 99, 101, 103-112, 117-127, and 147.

15. An isolated IL-23p19 antibody, comprising the light chain variable region of claim 13 and the heavy chain variable region of claim 14.

16. An antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody according to any of claims 1-15.

17. An IL-23p19 antibody according to any of claims 1-16, wherein said antibody binds IL-23p19 with at least one affinity selected from at least 10^{-9} M, at least 10^{-10} M, at least 10^{-11} M, and at least 10^{-12} M, at least 10^{-13} M, at least 10^{-14} M, and at least 10^{-15} M, as determined by surface plasmon resonance or the Kinexa method.

18. An IL-23p19 antibody according to any of claims 1-15, wherein said antibody substantially modulates at least one activity of at least one IL-23 polypeptide.

19. An isolated nucleic acid molecule encoding at least one isolated IL-23p19 antibody according to any of claims 1-15.

20. An isolated nucleic acid molecule comprising at least one of:

a light chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS:136-138 and 142-144; and

a heavy chain variable region nucleotide sequence selected from the group consisting of SEQ ID NOS:133-135 and 139-141.

21. An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claims 19 or 20.

22. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claims 19 or 20.

23. The host cell according to claim 22, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

24. A method for producing at least one IL-23p19 antibody, comprising translating the nucleic acid molecule according to claims 19 or 20 under conditions in vitro, in vivo or in situ, such that the IL-23p19 antibody is expressed in detectable or recoverable amounts.

25. A composition comprising at least one isolated IL-23p19 antibody according to any of claims 1-15 and at least one pharmaceutically acceptable carrier or diluent.

26. A composition according to claim 25, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist.

27. Use of an antibody according to any of claims 1-15 in the manufacture of a medicament for diagnosing or treating an IL-23 related condition.

28. The use of a claim 27, wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, optic neuritis, and clinically isolated syndrome.

29. A medical device, comprising an IL-23p19 antibody according to any of claims 1-15, wherein said device is suitable for contacting or administering said IL-23p19 antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac,

intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

30. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-23p19 antibody according to any of claims 1-15.

31. The article of manufacture of claim 33, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

32. A method for producing an isolated IL-23p19 antibody according to any of claims 1-15, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

33. An IL-23p19 antibody produced by the method according to claim 32.

34. An isolated IL-23p19 antibody, comprising a light chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS: 136-138 and 142-144.

35. An isolated IL-23p19 antibody, comprising a heavy chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS: 133-135 and 139-141.

36. An isolated IL-23p19 antibody, comprising the light chain variable region sequence of claim 37 and the heavy chain variable region sequence of claim 38.

37. An isolated IL-23p19 antibody, comprising a light chain variable region sequence encoded by a nucleotide sequence having at least 95% identity to any of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 136-138 and 142-144.

38. An isolated IL-23p19 antibody, comprising a heavy chain variable region sequence encoded by a nucleotide sequence having at least 95% identity to any of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 133-135 and 139-141.

39. An isolated IL-23p19 antibody, comprising the light chain variable region sequence of claim 41 and the heavy chain variable region sequence of claim 41.

40. An antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody according to any of claims 37-42.

41. An IL-23p19 antibody according to any of claims 37-42, wherein said antibody binds IL-23p19 with at least one affinity selected from at least 10^{-9} M, at least 10^{-10} M, at least 10^{-11} M, and at least 10^{-12} M, at least 10^{-13} M, at least 10^{-14} M, and at least 10^{-15} M, as determined by surface plasmon resonance or the Kinexa method.

42. An IL-23p19 antibody according to any of claims 37-42, wherein said antibody substantially modulates at least one activity of at least one IL-23 polypeptide.

43. An isolated nucleic acid molecule comprising at least one nucleotide sequence according to any of claims 37, 38, 40 and 41.

44. An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claim 43.

45. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 46.

46. The host cell according to claim 48, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof.

47. A method for producing at least one IL-23p19 antibody, comprising translating the nucleic acid molecule according to claim 46 under conditions in vitro, in vivo or in situ, such that the IL-23p19 antibody is expressed in detectable or recoverable amounts.

48. A composition comprising at least one isolated IL-23p19 antibody according to any of claims 37-42 and at least one pharmaceutically acceptable carrier or diluent.

49. A composition according to claim 50, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist.

50. Use of a IL-23 antibody according to any of claims 29-42 in the manufacture of a medicament for diagnosing or treating an IL-23 related condition in a cell, tissue, organ or animal.

51. The use according to claim 53 wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, optic neuritis, and clinically isolated syndrome.

52. The use according to claim 53, wherein said IL-13 antibody is present in an amount about 0.001-50 mg/kilogram of said cells, tissue, organ or animal.

53. A medical device, comprising an IL-23p19 antibody according to any of claims 37-42, wherein said device is suitable for contacting or administering said IL-23p19 antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

54. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-23p19 antibody according to any of claims 37-42.

55. The article of manufacture of claim 30, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

56. A method for producing an isolated IL-23p19 antibody according to any of claims37-42, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

57. An IL-23p19 antibody produced by the method according to claim 33.

WHAT IS CLAIMED IS:

1. An isolated IL-23p19 antibody, wherein said antibody is fully human generated from phage display and binds to human IL-23p19 at one or more of amino acid residues 93-105 of SEQ ID NO: 145.

2. An antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody according to claim 1.

3. An IL-23p19 antibody according to claim 1, wherein said antibody binds IL-23p19 with at least one affinity selected from at least 10^{-9} M, at least 10^{-10} M, at least 10^{-11} M, and at least 10^{-12} M, at least 10^{-13} M, at least 10^{-14} M, and at least 10^{-15} M, as determined by surface plasmon resonance or the Kinexa method.

4. An IL-23p19 antibody according to claim 1, wherein said antibody substantially modulates at least one activity of at least one IL-23 polypeptide.

5. An isolated nucleic acid molecule encoding at least one isolated IL-23p 19 antibody according to claim 1.

6. An isolated nucleic acid vector comprising the isolated nucleic acid molecule according to claim 5.

7. A prokaryotic or eukaryotic host cell comprising the isolated nucleic acid molecule according to claim 5.

8. The host cell according to claim 7, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK2I, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, or lymphoma cells, or any derivative, immortalized or transformed cell thereof

9. A method for producing at least one IL-23p19 antibody, comprising translating the nucleic acid molecule according to claim 5 under conditions in vitro, in vivo or in situ, such that the IL-23p19 antibody is expressed in detectable or recoverable amounts.

10. A composition comprising at least one isolated IL-23p19 antibody according to claim 1 and at least one pharmaceutically acceptable carrier or diluent.

11. A composition according to claim 10, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (ANS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an opthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist.

12. Use of an antibody according to claim 1 in the manufacture of a medicament for diagnosing or treating an IL-23 related condition.

13. The use of claim 12, wherein the IL-23 related condition is selected from the group consisting of psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, optic neuritis, and clinically isolated syndrome.

14. A medical device, comprising an IL-23p19 antibody according to claim 1, wherein said device is suitable for contacting or administering said IL-23p19 antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

15. An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of an IL-23p19 antibody according to claim 1.

16. The article of manufacture of claim 15, wherein said container is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial,

intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebraventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system.

17. A method for producing an isolated IL-23p19 antibody according to claim 1, comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

18. An IL-23p19 antibody produced by the method according to claim 17.